Jorge Alatorre-Alexander

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen V. Liu, Martin Reck, Aaron S. Mansfield et al. · Journal of Clinical Oncology · 2021 · 824 citations · Full text

Medicine, Oncology, Pharmacology +16

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

Melissa L. Johnson, Byoung Chul Cho, Alexander Luft et al. · Journal of Clinical Oncology · 2022 · 434 citations · Full text

Medicine, Oncology, Pharmacology +17

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

Medicine, Oncology, Pharmacology +14

Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC

James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi et al. · New England Journal of Medicine · 2025 · 85 citations

Medicine, Oncology, Pharmacology +15

Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study

Óscar Arrieta, Cynthia Villarreal‐Garza, Luis Manuel Martínez-Barrera et al. · BMC Cancer · 2013 · 74 citations · Full text

Medicine, Oncology, Chemotherapy +16